| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.79B | +11.3% |
| Gross profit | ¥0.16B | — |
| Operating income | ¥0.08B | — |
| Net income | ¥0.07B | +16.8% |
| Gross margin | 20.4% | Net margin 8.7% |
| Revenue Q/Q | +0.9% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.63B | 79.6% |
| R&D | ¥0.02B | 2.3% |
| SG&A | ¥0.05B | 5.8% |
| Tax & other | ¥0.01B | 1.4% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
拓尔思 ・ 永利股份 ・ 银信科技 ・ 洲明科技 ・ 金城医药 ・ 开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies